Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

Cardioprotective Flush, Without Reanimation, Safe and Effective in DCD Transplant

News Daily News

Cardioprotective Flush, Without Reanimation, Safe and Effective in DCD Transplant

Michael O'Riordan

January 28, 2026

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

News Conference News AHA 2025

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

November 14, 2025

Cardiac Transplant in Midst of ‘Revolution,’ but Public Trust Is Fragile

News Features

Cardiac Transplant in Midst of ‘Revolution,’ but Public Trust Is Fragile

Michael O'Riordan

October 17, 2025

Getting Ready for a Heart Failure Polypill, Well Before the Data Are In

News Daily News

Getting Ready for a Heart Failure Polypill, Well Before the Data Are In

October 16, 2025

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

October 02, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

GDMT Rates Low in HFrEF, Particularly in Women

News Daily News

GDMT Rates Low in HFrEF, Particularly in Women

January 30, 2024

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

August 30, 2023

May 2023 News Roundup

News Opinion CV Team Dispatch

May 2023 News Roundup

May 01, 2023

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

News Daily News

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

Michael O'Riordan

June 16, 2021

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

September 16, 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

September 01, 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

March 26, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.